According to Zhitong Finance App News, Rebon Pharmaceutical-B (09637.HK) announced that the board of directors has decided to buy back the company's H shares from time to time on the Hong Kong Stock Exchange Limited's open market in accordance with the general authorization granted to the company's directors at the extraordinary shareholders' meeting held on August 14, 2026, for a total amount not exceeding HK$100 million (including transaction costs such as brokerage commissions and stamp duties).

According to Zhitong Finance App News, Rebon Pharmaceutical-B (09637.HK) announced that the board of directors has decided to buy back the company's H shares from time to time on the Hong Kong Stock Exchange Limited's open market in accordance with the general authorization granted to the company's directors at the extraordinary shareholders' meeting held on August 14, 2026, for a total amount not exceeding HK$100 million (including transaction costs such as brokerage commissions and stamp duties).